╪1,3Margo Waters, ╪1,3Juliane Hopf, 1,3Paul Helquist, 2Vincent Jo Davisson, and 1,3Prakash. D. Nallathamby
1University of Notre Dame, Notre Dame USA; 2Purdue University, Lafayette, USA; 3NDnano, Notre Dame, USA
╪ Equal contributors
The leading cause of fatalities in breast cancer is metastasis.1 To increase the success rate of metastasis-free survival, there is a need to tackle therapy-resistant metastatic forms of the disease with novel, patient-friendly, combinatorial treatment regimens. At present, doxorubicin (Dox) regimens are standard of care for tumor debulking but do not stop metastatic recurrence and present cardiotoxicity. Vacuolar ATPase (V-ATPase) H+ pump inhibitors (e.g., diphyllins) prevent metastasis, but the ubiquitous occurrence of this target raises concerns of off-target toxicity.2 A solution is targeted delivery to reduce off-target effects while also minimizing drug dose side-effects.3 So, here we present the successful demonstration of targeted combinatorial-delivery of V-ATPase inhibitors (Diph) and standard chemotherapeutics (Dox) to the MDAMB231 triple negative breast cancer metastatic cell model (2D and 3D) with positive cell clearance and affirmative inhibition of cancer cell invasion. Our drug delivery system used a label-free magnetoelectric system.
Congratulations to Dr.
Hopf and undergraduate researcher Margo Waters for their contributions to these excellent results.
References :  Dubey, A.K., et al. Asian Pac J Cancer Prev 16, 4237-45 (2015).  McHenry, P. et al. J Cell Biochem 109, 634-42 (2010).  Huang, T. et al. Anal Chem 79, 7708-18 (2007).